Who founded Alterome Therapeutics, Inc.?

Alterome Therapeutics, Inc. was founded by Eric A. Murphy in 2021.

Who are Alterome Therapeutics, Inc.'s investors?

Alterome Therapeutics, Inc.'s investors include Canaan Partners, Nextech Invest, OrbiMed, Vida Ventures, Digitalis Ventures, NVIDIA.

How much funding has Alterome Therapeutics, Inc. raised?

Alterome Therapeutics, Inc. has disclosed $63.8M raised across 1 round.

Where is Alterome Therapeutics, Inc. headquartered?

Alterome Therapeutics, Inc. is headquartered in San Diego, US.

Alterome Therapeutics, Inc.

San Diego, US · Founded 2021 · Delaware corporation · 42 employees on LinkedIn · 6 known investors

Find your way into Alterome Therapeutics, Inc.

Each arrow is one introduction. Sign up to fill in the first one.

10 people can intro you to Eric

Ask Lucy Liu to introduce you to Eric A. Murphy

You →Lucy · together at Sidewinder Therapeutics →Eric

Your email: who you already know at Alterome Therapeutics, Inc., and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Alterome Therapeutics, Inc. team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic. It focuses on hard-to-drug cancer targets such as mutant KRAS and mutant AKT E17K across malignancies including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancers.

AI & Machine Learning Biotech Deep Tech

Founders & leadership

Alterome Therapeutics, Inc. was founded in 2021 by Eric A. Murphy.

Eric A. Murphy CEO, CSO, and Co-Founder2021–2024Eric A. Murphy leads Alterome Therapeutics, a clinical-stage precision oncology company developing small-molecule therapies targeting mutant KRAS and mutant AKT across multiple cancer types. He has held roles in academic, biotech, pharmaceutical, and contract research organizations, with expertise in cancer research, drug discovery, pharmacology, and drug development.

Ryan B. CorcoranNamed on SEC filing

Board

Thilo Schroeder Board directorGeneral Partner at Nextech Partners SCSp

Carl Gordon Board directorManaging Partner at OrbiMed

Arjun Goyal Member Board Of Directors2021–2025Investment committee member at Tin Alley Ventures

Investors · 6

Canaan Partnerslisted by Canaan PartnersStamford · $500K – $20M

How we know: Canaan Partners's portfolio page · Not right? Tell us

Nextech Investlisted by Nextech InvestZurich · $648K – $3.2M

How we know: Nextech Invest's portfolio page · a partner's Signal profile · Not right? Tell us

OrbiMedlisted by OrbiMedNew York · $1M – $75M

How we know: OrbiMed's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us

Vida Ventureslisted by Vida VenturesLos Angeles

How we know: Vida Ventures's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us

Digitalis VenturesreportedNew York · $100K – $10M

How we know: the VCSheet dataset · Not right? Tell us

NVIDIAreportedSanta Clara

How we know: funding news · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$63.8M disclosed across 1 round · 2021

▶$63.8MraisedJan 2022 · 9 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Eric A. MurphyExecutive Officer, Director, Promoter
Thilo SchroederDirector
Ryan B. CorcoranDirector, Promoter
Carl GordonDirector
Arjun GoyalDirector

Offering amount: $63.8M
Amount sold: $63.8M
First sale: Dec 2021
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Alterome Therapeutics, Inc. went on to found or lead other companies.

Dr Arjun GoyalDirectorFounded Affini-T Therapeutics Eric A. MurphyExecutive Officer, Director, PromoterFounded Sidewinder Therapeutics

Related companies · 8

ImmunomeImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.

Noveome BiotherapeuticsNoveome is a clinical-stage biopharmaceutical company developing ST266, a multi-targeted secretome containing hundreds of biologically active proteins designed for neuroprotection, inflammation modulation, and tissue healing. The company is investigating ST266's potential across ophthalmology, neurology, dermatology, and other therapeutic areas.

NucleomeNucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets. The company builds a data atlas of immune system dysregulation to enable development of genetically-informed therapeutics for inflammatory conditions.

CellanomeCellanome develops a live-cell analysis platform using CellCage technology to create controlled microenvironments that enable researchers to observe cell behavior and molecular changes over time. The platform generates structured multimodal data for life sciences researchers and biopharma companies focused on oncology, neuroscience, immunology, and aging research.

nChroma BionChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications. The company works with academic founders and institutional investors focused on advancing gene therapy treatments.

MyomeMyOme provides genomic insights and clinical genetic screening reports to help individuals and healthcare providers assess risks for hereditary conditions and make informed health decisions.

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

FreenomeFreenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases. The company serves healthcare providers and patients seeking preventive cancer screening solutions.

Companies working in the same space as Alterome Therapeutics, Inc..

Frequently asked questions

What does Alterome Therapeutics, Inc. do?: Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic. It focuses on hard-to-drug cancer targets such as mutant KRAS and mutant AKT E17K across malignancies including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancers.
Who founded Alterome Therapeutics, Inc.?: Alterome Therapeutics, Inc. was founded by Eric A. Murphy in 2021.
Who are Alterome Therapeutics, Inc.'s investors?: Alterome Therapeutics, Inc.'s investors include Canaan Partners, Nextech Invest, OrbiMed, Vida Ventures, Digitalis Ventures, NVIDIA.
How much funding has Alterome Therapeutics, Inc. raised?: Alterome Therapeutics, Inc. has disclosed $63.8M raised across 1 round.
Where is Alterome Therapeutics, Inc. headquartered?: Alterome Therapeutics, Inc. is headquartered in San Diego, US.